X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13779) 13779
Publication (538) 538
Book Review (174) 174
Magazine Article (80) 80
Newspaper Article (43) 43
Newsletter (36) 36
Dissertation (28) 28
Book Chapter (25) 25
Book / eBook (7) 7
Conference Proceeding (6) 6
Report (2) 2
Web Resource (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10197) 10197
streptokinase (5141) 5141
streptokinase - therapeutic use (4859) 4859
male (4613) 4613
female (4199) 4199
middle aged (3871) 3871
myocardial infarction - drug therapy (3302) 3302
aged (2901) 2901
thrombolytic therapy (2832) 2832
adult (2531) 2531
streptokinase - administration & dosage (2093) 2093
fibrinolytic agents - therapeutic use (1845) 1845
cardiac & cardiovascular systems (1750) 1750
time factors (1536) 1536
animals (1431) 1431
tissue plasminogen activator - therapeutic use (1161) 1161
fibrinolysis (1147) 1147
thrombolysis (1130) 1130
streptokinase - adverse effects (1069) 1069
deoxyribonuclease i (1066) 1066
acute myocardial-infarction (1012) 1012
treatment outcome (953) 953
heparin - therapeutic use (940) 940
intravenous streptokinase (863) 863
medicine, general & internal (857) 857
thrombosis - drug therapy (857) 857
therapy (836) 836
streptokinase - pharmacology (834) 834
myocardial infarction - mortality (833) 833
myocardial infarction - therapy (833) 833
myocardial infarction (812) 812
myocardial infarction - physiopathology (802) 802
electrocardiography (784) 784
urokinase-type plasminogen activator - therapeutic use (744) 744
peripheral vascular disease (728) 728
streptodornase and streptokinase (720) 720
fibrinolytic agents - administration & dosage (686) 686
coronary angiography (655) 655
tissue plasminogen-activator (655) 655
follow-up studies (639) 639
index medicus (614) 614
urokinase (604) 604
reperfusion (600) 600
mortality (596) 596
acute disease (594) 594
heart attack (588) 588
hematology (582) 582
trial (574) 574
thrombolytic therapy - methods (555) 555
recurrence (553) 553
pulmonary embolism - drug therapy (550) 550
clinical trials as topic (549) 549
thrombosis (548) 548
thrombophlebitis - drug therapy (544) 544
prognosis (532) 532
thrombolytic therapy - adverse effects (496) 496
heparin (495) 495
prospective studies (486) 486
plasminogen (485) 485
fibrinolysis - drug effects (477) 477
randomized trial (471) 471
surgery (469) 469
aged, 80 and over (467) 467
drug therapy, combination (467) 467
adolescent (462) 462
infusions, intravenous (460) 460
retrospective studies (449) 449
fibrinolytic agents - adverse effects (448) 448
plasminogen-activator (440) 440
myocardial infarction - diagnostic imaging (436) 436
drug therapy (432) 432
angioplasty (417) 417
angioplasty, balloon, coronary (411) 411
risk factors (411) 411
plasminogen - metabolism (407) 407
myocardial infarction - diagnosis (401) 401
tissue plasminogen activator - administration & dosage (394) 394
streptodornase and streptokinase - therapeutic use (390) 390
left-ventricular function (389) 389
acute myocardial infarction (388) 388
cardiovascular system (386) 386
injections, intravenous (385) 385
streptokinase - metabolism (377) 377
management (375) 375
rabbits (373) 373
child (372) 372
care and treatment (368) 368
angiography (367) 367
myocardial infarction - complications (367) 367
anticoagulants - therapeutic use (366) 366
dogs (366) 366
tissue plasminogen activator (364) 364
myocardial infarction - blood (359) 359
research (352) 352
heparin - administration & dosage (345) 345
plasminogen activators - therapeutic use (330) 330
combined modality therapy (328) 328
recombinant proteins - therapeutic use (322) 322
biochemistry & molecular biology (320) 320
radiography (315) 315
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10754) 10754
German (1214) 1214
French (464) 464
Russian (334) 334
Spanish (238) 238
Italian (217) 217
Polish (188) 188
Japanese (122) 122
Czech (74) 74
Portuguese (71) 71
Chinese (37) 37
Danish (36) 36
Dutch (32) 32
Hungarian (30) 30
Swedish (27) 27
Norwegian (25) 25
Romanian (24) 24
Ukrainian (19) 19
Turkish (15) 15
Hebrew (14) 14
Croatian (12) 12
Slovak (12) 12
Bulgarian (11) 11
Finnish (9) 9
Persian (7) 7
Serbian (5) 5
Afrikaans (2) 2
Korean (2) 2
Estonian (1) 1
Icelandic (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


FEBS Letters, ISSN 0014-5793, 05/2013, Volume 587, Issue 9, p. 1304
a* Two types of streptokinases (SK) have been found in different Streptococcus pyogenes strains, SK1 and SK2b. a* SK2b activity requires cell surface... 
Streptokinase
Journal Article
INDIGENOUS RECOMBINANT STREPTOKINASE VS NATURAL STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION PATIENTS: PHASE III MULTICENTRIC RANDOMIZED DOUBLE BLIND TRIAL, 12/2005
Background : Streptokinase is the most widely used thrombolytic agent and can now be made using recombinant DNA technology. The present trial was initiated to... 
Streptokinase, Recombinant streptokinase, Myocardial infarction, Thrombolysis
Journal
2012, SpringerBriefs in microbiology, ISBN 3642249795
Web Resource
Biotechnology and Bioengineering, ISSN 0006-3592, 01/2018, Volume 115, Issue 1, pp. 92 - 102
Journal Article
01/2007
Background: Cardiac catheterization like other invasive procedures is afflicted with complications, one of the most important complications is vessel... 
Streptokinase | Catheterization | Children | Thrombosis
Web Resource
Journal Article
Protein Expression and Purification, ISSN 1046-5928, 12/2016, Volume 128, pp. 14 - 21
Streptokinase is a valuable fibrinolytic agent used to cope with myocardial infarction and brain stroke. Despite its high efficiency in dissolving blood clots,... 
Chromogenic substrate assay | Kringle 2 | Fibrin-binding streptokinase | Fibrinolytic agent | H-1-NMR | ACTIVATOR KRINGLE-2 DOMAIN | STIMULATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | ESCHERICHIA-COLI | INVOLVEMENT | BIOCHEMICAL RESEARCH METHODS | STRUCTURAL-CHARACTERIZATION | PLASMINOGEN-ACTIVATOR | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | THROMBOLYTIC THERAPY | BINDING | Recombinant Fusion Proteins - isolation & purification | Tissue Plasminogen Activator - isolation & purification | Humans | Bacterial Proteins - chemistry | Tissue Plasminogen Activator - chemistry | Tissue Plasminogen Activator - genetics | Streptokinase - chemistry | Fibrin - chemistry | Escherichia coli - metabolism | Protein Engineering | Recombinant Fusion Proteins - biosynthesis | Streptokinase - biosynthesis | Streptokinase - genetics | Bacterial Proteins - genetics | Recombinant Fusion Proteins - chemistry | Fibrinolysis | Streptococcus - enzymology | Tissue Plasminogen Activator - biosynthesis | Streptococcus - genetics | Escherichia coli - genetics | Recombinant Fusion Proteins - genetics | Streptokinase - isolation & purification | Bacterial Proteins - biosynthesis | Fibrin - metabolism | Bacterial Proteins - isolation & purification | Stroke (Disease) | Fibrin | Tissue plasminogen activator | Analysis | Escherichia coli | Recombinant proteins | Protein binding
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2005, Volume 352, Issue 9, pp. 865 - 874
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 12, Issue 12, p. CD001099
Background Peripheral arterial thrombolysis is used in the management of peripheral arterial ischaemia. Streptokinase was originally used but safety concerns... 
LOWER-EXTREMITY | PROSPECTIVE RANDOMIZED-TRIAL | Humans | LIMB ISCHEMIA | LOCAL THROMBOLYSIS | Arterial Occlusive Diseases [drug therapy] | Peripheral Vascular Diseases [drug therapy] | Urokinase-Type Plasminogen Activator [adverse effects; therapeutic use] | Fibrinolytic Agents [adverse effects; therapeutic use] | Randomized Controlled Trials as Topic | Thrombosis [drug therapy] | Thrombolytic Therapy [adverse effects; methods] | MEDICINE, GENERAL & INTERNAL | STREPTOKINASE | Streptokinase [adverse effects; therapeutic use] | Tissue Plasminogen Activator [adverse effects; therapeutic use] | TISSUE-PLASMINOGEN-ACTIVATOR | Recombinant Proteins [adverse effects; therapeutic use] | THROMBOLYTIC THERAPY | UROKINASE | Recombinant Proteins - therapeutic use | Streptokinase - adverse effects | Urokinase-Type Plasminogen Activator - adverse effects | Urokinase-Type Plasminogen Activator - therapeutic use | Peripheral Vascular Diseases - drug therapy | Tissue Plasminogen Activator - therapeutic use | Recombinant Proteins - adverse effects | Streptokinase - therapeutic use | Tissue Plasminogen Activator - adverse effects | Fibrinolytic Agents - adverse effects | Arterial Occlusive Diseases - drug therapy | Fibrinolytic Agents - therapeutic use | Thrombolytic Therapy - methods | Thrombosis - drug therapy | Thrombolytic Therapy - adverse effects
Journal Article